{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-019862","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.775693+00:00","generated_at":"2026-05-26T22:22:32.003220+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AVITA Medical Q4 revenue $18.4M (+30% YoY), net loss $11.6M; FY2025 guidance $100-106M","bullets":["Q4 commercial revenue $18.4M (+30% YoY); gross margin 87.6%.","Net loss $11.6M ($0.44 loss per share) vs $7.1M loss in Q4 2023.","FY2025 revenue guidance $100-106M (55-65% growth); expects GAAP profitability in Q4 2025.","Amended OrbiMed credit agreement; adjusted revenue covenants for 2025-2026; issued warrants for 145,180 shares at $0.01/share.","FDA clearances: Cohealyx (Dec 2024) and RECELL GO mini (Dec 2024); full Cohealyx launch by April 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-019862","json":"https://secwatch.observer/filing/0000950170-25-019862.json","markdown":"https://secwatch.observer/filing/0000950170-25-019862.md","text":"https://secwatch.observer/filing/0000950170-25-019862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017025019862/0000950170-25-019862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017025019862/rcel-20250213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:22:32.003220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}